<DOC>
	<DOCNO>NCT01345214</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability ONO-7746 across multiple dos patient solid tumor chemotherapy induce thrombocytopenia ( CIT ) schedule receive least two cycle myelosuppressive chemotherapy Day 1 every 21 day dosage schedule study . The secondary objective characterize PK profile ONO-7746 explore pharmacodynamic effect ONO-7746 CIT .</brief_summary>
	<brief_title>A Study Safety Efficacy ONO-7746 Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Signed write informed consent Age ≥ 18 year Patients confirm solid tumor schedule receive least two cycle myelosuppressive chemotherapy Day 1 every 21 day dosage schedule study . Experienced thrombocytopenia evidence platelet count &lt; 100 Gi/L precede cycle immediately study enrollment . ECOG performance status ≤ 2 For female , surgically sterilize , postmenopausal agree use acceptable form birth control Patients treat novel anticancer agent ( e.g . bevacizumab , erlotinib , trastuzumab , cetuximab ) may allow consider standard treatment investigator consultation approval Sponsor PT/INR aPTT within 80 % 120 % normal range Experienced thrombocytopenia evidence platelet count &lt; 25 Gi/L time precede cycle immediately enrollment study History presence clinically significant disease Received TRAs , rHuIL11 within last 4 week prior screen Had receive bone marrow peripheral blood stem cell infusion ( within 1 year screening ) . Pregnant , want become pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>ONO-7746</keyword>
	<keyword>Chemotherapy Induced Thrombocytopenia</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>